Source: Orezone Gold Corp.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Orezone Gold Corporation (ORE) has closed its previously announced non-brokered private placement for gross proceeds of $16,510,000
  • The net proceeds will be used to advance several project development initiatives
  • Orezone Gold is a Canadian mining company operating the open pit Bomboré Gold Mine
  • Orezone Gold Corporation (ORE) opened trading at C$1.26

Orezone Gold Corporation (ORE) has closed its previously announced non-brokered private placement with a large institutional fund.

Under the offering, the company issued 13,000,000 common shares at a price of $1.27 for gross proceeds of $16,510,000.

The net proceeds will be used to advance several initiatives, including project development at Bomboré ahead of the Phase II sulphide expansion, additional targeted exploration drilling, and advancement of Orezone’s corporate growth strategy in the region.

All common shares issued will be subject to a statutory four-month hold period. A finder’s fee is payable in connection with the offering.

Orezone Gold Corporation is a Canadian mining company operating the open pit Bomboré Gold Mine in Burkina Faso.

Orezone Gold Corporation (ORE) opened trading at C$1.26.


More From The Market Herald

" ParcelPal (CSE:PKG) relaunches a new and improved mobile application

ParcelPal Logistics (PKG) will relaunch its mobile delivery application on a rolling basis over the coming months.

" Puma Exploration (TSXV:PUMA) confirms mineralization

Puma Exploration (PUMA) is confirming mineralization at its Williams Brook Gold Project in Northern New Brunswick.
Flying Nickel Mining

" Flying Nickel (TSXV:FLYN) confirms platinum, palladium, gold mineralization

Flying Nickel Mining (FLYN) is confirming, it uncovered gold mineralization from the most-recent drill program on its Minago Nickel PGM Project.

" NervGen Pharma (TSXV:NGEN) releases year-end operational highlights

NervGen Pharma (NGEN) reports 2022 year-end operational highlights and looks to start a phase 1b/2a clinical trial in Q3 2023.